High molecular weight hyaluronan for treatment of chronic shoulder pain associated with glenohumeral arthritis

Arnold J Weil
Non-Surgical Orthopedics PC, Marietta, GA, USA

Background: There is insufficient evidence to determine whether intra-articular injections may be effective for treatment of glenohumeral osteoarthritis. Euflexxa® (high molecular weight hyaluronate), a bioengineered high molecular weight hyaluronan, has been shown to be a safe and effective treatment for patients with knee osteoarthritis. There is also support for the use of hyaluronate injection for the treatment of chronic shoulder pain associated with osteoarthritis or rotator cuff damage. This small-scale exploratory study was conducted to evaluate the safety and efficacy of high molecular weight hyaluronate for the treatment of chronic shoulder pain associated with osteoarthritis.

Methods: Subjects with glenohumeral osteoarthritis and chronic pain (n = 27) received one injection per week for 3 weeks of high molecular weight hyaluronate and were assessed for changes in pain (100 mm visual analog scale [VAS]), range of motion, and the subject's and physician's global assessment over 26 weeks. Subjects were also assessed for pain, stiffness, and physical functioning using the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Finally, responses were evaluated using modified Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) Proposition D criteria. Safety was assessed by recording adverse events.

Results: High molecular weight hyaluronate significantly improved pain (VAS, WOMAC), range of motion, stiffness, and physical functioning scores; 77.8% of subjects were rated as having an OMERACT-OARSI Proposition D high response. There were no serious adverse events, and none were considered to be related to treatment.

Conclusion: Treatment with high molecular weight hyaluronate improves pain, stiffness, and range of motion, and may have an acceptable safety and tolerability profile. A randomized, double-blind, placebo-controlled clinical trial may be warranted to investigate further the efficacy and safety of intra-articular high molecular weight hyaluronate for treatment of chronic shoulder pain in patients with glenohumeral osteoarthritis.

Keywords: Euflexxa®, hyaluronan, osteoarthritis, pain, range of motion, shoulder

Introduction

Persistent shoulder pain, regardless of the definition used, is a common disorder. A survey of 312 general practice patients in the United Kingdom indicated that 31%–48% had shoulder pain depending on the definition used, and 27% of all respondents had shoulder pain regardless of the definition.1 Results summarized in a comprehensive review of shoulder disorders indicated that the annual incidence of this condition is about 7%, the 1-year prevalence is 51%, and the lifetime prevalence is approximately 10%.2
Chronic shoulder pain can result from bursitis, tendinitis, rotator cuff tear, adhesive capsulitis, impingement syndrome, necrosis, glenohumeral osteoarthritis, and degenerative joint disease.\(^5\) Rotator cuff disorders, adhesive capsulitis, and glenohumeral osteoarthritis are all common causes. Analysis of 692 office visits for shoulder pain collected through the National Ambulatory Medical Care Survey from 1993 to 2000 indicated that rotator cuff syndrome of the shoulder was the most common diagnosis (9.6%), followed by shoulder pain not otherwise specified (8.5%) and osteoarthritis (5.6%).\(^4\) Degenerative joint disease of the shoulder is also common. The shoulder is the third most common joint to require surgical reconstruction after the knee and hip.\(^5\) The prevalence of idiopathic adhesive capsulitis ranges from 0.2% to 5.0% and it is most common in elderly patients.\(^6\)

Effective treatment of chronic shoulder pain depends on an accurate diagnosis of the more common etiologies, ie, rotator cuff disorders, adhesive capsulitis, acromioclavicular osteoarthritis, glenohumeral osteoarthritis, and instability. Activity modification and analgesic medications comprise the initial treatment in most cases. If this does not lead to improvement, or if the initial presentation is of sufficient severity, a trial of physical therapy that focuses on the specific diagnosis is indicated. Combined steroid and local anesthetic injections can be used alone or as an adjuvant to physical therapy.\(^7,8\) There is insufficient evidence to support or refute the use of oral pharmacologic treatments for shoulder arthritis. There is also insufficient evidence to determine whether intra-articular steroid injection is effective for the treatment of glenohumeral osteoarthritis. As few as 20% of patients with chronic shoulder pain self-report complete recovery after therapeutic intervention, and current recommendations support few nonsurgical options for the treatment of shoulder osteoarthritis.\(^5,8,10\)

There is limited support for the use of hyaluronan injection for the treatment of chronic shoulder pain associated with osteoarthritis or rotator cuff damage. Meta-analysis of results from 19 randomized controlled trials (2120 participants) revealed that intra-articular injection of hyaluronate can decrease symptoms of chronic painful shoulder. This treatment was associated with reductions in pain and improvements in total functional scores. Results from a study of 30 consecutive patients with idiopathic glenohumeral osteoarthritis who failed to respond to standard conservative measures and then received weekly intra-articular hyaluronate injections over 3 weeks in their affected shoulders indicated that this treatment significantly improved pain at 6-month follow-up.\(^11\) A study of 660 patients with persistent shoulder pain and limitations resulting from glenohumeral joint osteoarthritis, rotator cuff tear, and/or adhesive capsulitis in whom conventional therapy failed and who received either intra-articular hyaluronate or phosphate-buffered saline solution, was conducted, with patient follow-up for 26 weeks. Patients who received hyaluronate had greater pain relief than control subjects, and this effect was driven by results from patients with osteoarthritis. There was no significant benefit of treatment in patients with either rotator cuff tendonitis or adhesive capsulitis.\(^13\) Results from 93 elderly patients with rotator cuff tear arthropathy indicated that treatment with hyaluronate significantly decreased symptoms for 4 months.\(^14\) Intra-articular hyaluronate injection was also shown to decrease pain and improve range of motion and ability to accomplish daily activities in a study of 51 patients with rotator cuff lesions but no tears.\(^15\)

Euflexxa\(^\text{®}\) (1% sodium hyaluronate) is a highly purified high molecular weight hyaluronate preparation produced by bioengineering and extracted from bacterial cells.\(^16\) It has been shown to be safe and effective for treatment of patients with knee osteoarthritis.\(^17,18\) The purpose of this study was to evaluate the safety and efficacy of high molecular weight hyaluronate using three intra-articular injections for treatment of chronic shoulder pain associated with glenohumeral osteoarthritis.

**Methods**

This was a nonrandomized, open-label study conducted in compliance with and according to 21 CRF Parts 50, 54, 56, and 812. The final protocol was approved by the Sterling local institutional review board. The study, conducted at a single center, aimed to enroll 25 subjects. All subjects were required to be 30–79 years of age, provide written informed consent, have shoulder pain for at least 6 months but less than 5 years, with a pain intensity score >5, and be willing to discontinue all pain medications 4 hours before each clinic visit. Twenty-seven of 32 subjects recruited for the study met these criteria and had a diagnosis of osteoarthritis confirmed by radiographs taken within the previous 6 months and chronic pain with osteoarthritis as the primary source. Enrolled subjects also had a limited shoulder range of motion in at least one direction for the following active range of motions: internal rotation 60\(^\circ\), external rotation of 80\(^\circ\), or abduction with scapula fixed of 80\(^\circ\), and had an active range of motion of at least 40% in all directions. The pain medication regimen must have been stable for at least 1 month before treatment and subjects agreed to maintain pain medication doses within ± 30% of the baseline dose during the course of the study.

Subjects were excluded if they had a history of full-thickness rotator cuff tear or joint effusion, a diagnosis
of chronic acromioclavicular disease, active epicondylitis, or active carpal tunnel disease, had more than two corticosteroid injections in the previous 3 months, or had an infection or inflammatory condition of the trial shoulder. Other grounds for exclusion were acute or inflammatory arthropathy in the trial shoulder, history of systemic inflammatory arthropathies, diagnosis of cancer within 5 years, receipt of any hyaluronate agent or other chondroprotective agents in the trial shoulder, hypersensitivity to hyaluronate products, eggs, birds, or feathers, and history of substance abuse, alcohol abuse, or a psychiatric condition, that, in the opinion of the investigator, could interfere with participation in the study. Subjects were also excluded for any medical condition that might increase the risk associated with intra-articular injections or other concomitant diseases that, in the opinion of the investigator, would interfere with the evaluation of the trial treatment. Individuals involved in litigation involving workers’ compensation, who were pregnant, planning to become pregnant or lactating, or who had participated in a clinical trial within the past 4 weeks were also excluded. All subjects received three injections (one each, in weeks 0 [baseline], 1, and 2) of high molecular weight hyaluronate (2.5 mL each) using standard injection techniques in the anterior or posterior approach. Subjects were evaluated at screening and baseline, and at weeks 1, 2, 6, 14, and 26 (last evaluation by telephone).

**Efficacy**

Efficacy assessments included: pain, measured on a 100 mm visual analog scale at baseline and weeks 1, 2, 3, 6, 14, and 26; range of motion, measured as a percentage at baseline and weeks 1, 2, 3, 6, 14, and 26; subject’s global assessment, measured on a five-point scale (higher score corresponds to worse condition) at weeks 3, 6, 14, and 26; physician’s global assessment, measured on a 100 mm visual analog scale at the same times; internal and external rotation of the shoulder and scapula degrees, measured at baseline and weeks 1, 2, 3, 6, 14, and 26; and Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain, stiffness, and physical functioning measured at baseline and weeks 1, 2, 3, 6, 14, and 26. Responses to treatment were also evaluated using modified Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) Proposition D criteria. A high response was defined as $\geq 50\%$ or $\geq 20$-point improvement in pain as measured by the 100 mm visual analog scale, or in range of motion as measured by the 100-point American Shoulder and Elbow Surgeons (ASES) shoulder score of $\geq 50\%$ and absolute change of $\geq 20$ mm. Moderate improvement was defined as having met at least two of the following: pain reduction $\geq 20\%$ and absolute change $\geq 10$ points; ASES shoulder score $\geq 20\%$ and a change of $\geq 10$ points on a 100-point scale; and/or subject global assessment $\geq 20\%$ and absolute change $\geq 10$ points. Safety was assessed by recording adverse events. Changes from baseline in means values for all efficacy variables were evaluated by means of paired $t$-tests.

**Results**

**Subjects**

Of the 32 subjects recruited for the study, five failed the screening visit and were excluded from the analysis. Efficacy and safety analyses were based on the remaining 27 subjects who were enrolled and completed the trial. Baseline demographic and clinical characteristics for these subjects are summarized in Table 1.

**Table 1** Subject demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Demographics (n = 27)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (n [%])</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14 (51.9)</td>
</tr>
<tr>
<td>Female</td>
<td>13 (48.1)</td>
</tr>
<tr>
<td>Age, years (mean [SD])</td>
<td>59.1 (10.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical characteristics at visit 1</th>
<th>n</th>
<th>Mean (SD)</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain VAS scores, mm</td>
<td>27</td>
<td>56.37 (16.62)</td>
<td>5.0</td>
<td>83.0</td>
</tr>
<tr>
<td>Total pain assessment</td>
<td>27</td>
<td>6.70 (1.17)</td>
<td>5.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Degree of internal rotation</td>
<td>27</td>
<td>47.04 (15.71)</td>
<td>15.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Degree of external rotation</td>
<td>27</td>
<td>64.96 (16.48)</td>
<td>20.0</td>
<td>85.0</td>
</tr>
<tr>
<td>Scapula degree</td>
<td>27</td>
<td>87.52 (19.13)</td>
<td>40.0</td>
<td>160.0</td>
</tr>
<tr>
<td>Range of motion, %</td>
<td>27</td>
<td>76.81 (12.27)</td>
<td>50.0</td>
<td>100.0</td>
</tr>
<tr>
<td>WOMAC pain VAS scores, mm</td>
<td>25</td>
<td>14.44 (5.45)</td>
<td>3.0</td>
<td>23.0</td>
</tr>
<tr>
<td>WOMAC stiffness scores</td>
<td>25</td>
<td>11.84 (4.06)</td>
<td>0.0</td>
<td>18.0</td>
</tr>
<tr>
<td>WOMAC physical functioning scores</td>
<td>25</td>
<td>72.12 (25.94)</td>
<td>17.0</td>
<td>124.0</td>
</tr>
</tbody>
</table>

**Abbreviations:** VAS, visual analog score; WOMAC, Western Ontario and McMaster Universities Arthritis Index; SD, standard deviation.
Efficacy

Treatment with high molecular weight hyaluronate significantly improved both pain (visual analog scale) and range of motion (%) over 26 weeks of follow-up (both \( P < 0.0001 \), Figure 1). Treatment with high molecular weight hyaluronate significantly improved (decreased) WOMAC pain scores, WOMAC stiffness scores, and WOMAC physical functioning scores over 26 weeks of follow-up (all \( P < 0.0001 \), Figure 2). Treatment also resulted in a significantly improved range of motion over 26 weeks of follow-up, including internal rotation (\( P < 0.0001 \), Figure 3A), external rotation (\( P < 0.0001 \), Figure 3B), and scapular degrees (\( P < 0.0001 \), Figure 3C). Treatment with high molecular weight hyaluronate also significantly improved both subject’s and physician’s global assessments at 26 weeks after treatment (\( P = 0.0006 \) and \( P = 0.0011 \), respectively; Figure 4).

Based on OMERACT-OARSI Proposition D criteria that combined three outcome measures at the end of the trial, 21 subjects (77.8%) were considered to have a high response and six subjects (22.2%) were considered to be nonresponders (Figure 5). Logistic regression examined the impact of age and gender on the likelihood of being a responder, and no significant effect of either of these variables was found.

Safety

Fourteen subjects reported a total of 47 adverse events. The most common adverse event was shoulder pain (nine reports); all but two adverse events were mild or moderate in severity (the severe adverse events were lethargy and slurred speech).
There were no serious adverse events, and no adverse events were considered to be related to treatment. No subjects discontinued treatment due to adverse events.

Discussion

Results from this exploratory, small-scale, open-label study showed that treatment of chronic shoulder pain secondary to glenohumeral osteoarthritis with high molecular weight hyaluronate decreased pain and increased range of motion.

Treatment with intra-articular high molecular weight hyaluronate also improved WOMAC pain, stiffness, and physical function, as well as subject's and physician's global assessments. In addition, 77.8% of subjects were considered high responders to treatment based on OMERACT-OARSI Proposition D criteria. Treatment with high molecular weight hyaluronate had an acceptable safety profile in subjects with chronic shoulder pain secondary to osteoarthritis. No treatment-related adverse events were reported, and all-causality adverse events were almost all mild or moderate in severity.

The results of this study are consistent with other reports indicating that intra-articular hyaluronate is effective for the treatment of persistent shoulder pain associated with glenohumeral osteoarthritis.11–13 These results also support the view expressed by the American Academy of Orthopedic Surgeons that the use of injectable viscosupplementation is an option for treating patients with glenohumeral joint osteoarthritis, and that hyaluronate injections have significant benefit.
in pain relief, range of motion, and quality of life. The safety of high molecular weight hyaluronate in the present study is consistent with results from two larger scale trials of this preparation in patients with knee osteoarthritis.17,18

Although nonavian-derived high molecular weight hyaluronate was not directly compared with hyaluronates derived from avian sources in this study, bioengineered, nonavian, and nonchemically cross-linked high molecular weight hyaluronate may have safety advantages over avian-derived hyaluronate preparations as well as hyaluronate preparations that achieve high molecular weight using chemically induced cross-linking. No adverse effects of avian-derived hyaluronate were reported in one small-scale, double-blind, placebo-controlled study for hyaluronate treatment of rotator cuff lesions without complete tears.15 However, hyaluronan preparations that achieve high molecular weight via chemically induced cross-linking have been associated with pseudoarthritis, a rare localized inflammatory reaction characterized by joint effusion, pain, and infiltration of inflammatory cells, in several large-scale studies for hyaluronate treatment of knee osteoarthritis.19-28

The major limitations of this study are that it is a small-scale, open-label study which did not include a placebo control group. However, the results of this and other studies suggest that there may be a need to evaluate further the safety and efficacy of intra-articular hyaluronate for treatment of chronic shoulder pain in a large-scale, multicenter, double-blind, placebo-controlled clinical trial.

A recent review of treatments for chronic shoulder pain concluded that “... there are no known interventions that alter the natural history of early osteoarthritis; therefore, the main objectives in treatment are to control pain and restore function”.25 There is a clear need for treatment with the potential to alter the natural history of shoulder osteoarthritis. While there is no evidence regarding disease-modifying activity for intra-articular hyaluronate in patients with shoulder osteoarthritis, a growing body of evidence supports the possibility that this treatment may have disease-modifying activity in knee osteoarthritis, including effects in the synovium and extracellular matrix of the articular cartilage, subchondral bone, matrix proteoglycans, and collagens.19,28 Further study will be necessary to address the potential disease-modifying properties of viscosupplementation agents.

**Conclusion**

The results of this study and others suggest that intra-articular high molecular weight hyaluronate may be a safe and effective treatment for shoulder pain associated with glenohumeral osteoarthritis. However, this was a small-scale, open-label study which did not include a placebo control group. A large-scale, multicenter, double-blind, placebo-controlled clinical trial is necessary to evaluate further the safety and efficacy of intra-articular hyaluronate for treatment of chronic shoulder pain. In addition, although a growing body of evidence supports the possibility that intra-articular hyaluronates may have disease-modifying activity in knee osteoarthritis, there is no evidence regarding disease-modifying activity for intra-articular hyaluronate in patients with shoulder osteoarthritis.

**Acknowledgments**

The author is indebted to all patients who participated in this study. Data analysis was done by Hind T Hatoum and Company, Chicago, IL.

**Disclosure**

The study was supported by Ferring Pharmaceuticals Inc.

**References**